Seroclinical association of anti-Th/To and anti-Rpp25 antibodies.
| Th/To+ by IP (N = 19) | Th/To– by IP (N = 31) | p | RP25+ by ELISA (N = 10) | RP25– by ELISA (N = 40) | p | RP25+ by CLIA (N = 12) | RP25– by CLIA (N = 38) | p | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean or % | SD or N | Missing | Mean or % | SD or N | Missing | Mean or % | SD or N | Missing | Mean or % | SD or N | Missing | Mean or % | SD or N | Missing | Mean or % | SD or N | Missing | ||||
| Female | 89.5% | 17 | 0 | 80.7% | 25 | 0 | 0.6933 | 80.0% | 8 | 0 | 85.0% | 34 | 0 | 0.6527 | 83.3% | 10 | 0 | 84.2% | 32 | 0 | 1.0000 |
| Age, yrs | 52.4 | 10.7 | 0 | 55.3 | 11.8 | 0 | 0.4530 | 50.3 | 11.7 | 0 | 55.2 | 11.3 | 0 | 0.3625 | 49.6 | 10.7 | 0 | 55.7 | 11.3 | 0 | 0.1166 |
| Meet 1980 ACR classification | 79.0% | 15 | 0 | 80.7% | 25 | 0 | 1.0000 | 80.0% | 8 | 0 | 80.0% | 32 | 0 | 1.0000 | 83.3% | 10 | 0 | 79.0% | 30 | 0 | 1.0000 |
| Disease duration | 11.0 | 10.5 | 0 | 11.2 | 11.4 | 0 | 0.7950 | 10.8 | 9.7 | 0 | 11.3 | 11.3 | 0 | 0.8367 | 9.6 | 9.2 | 0 | 11.6 | 11.5 | 0 | 0.9006 |
| Diffuse disease, % | 10.5% | 2 | 0 | 32.3% | 10 | 0 | 0.1003 | 10.0% | 1 | 0 | 27.5% | 11 | 0 | 0.4155 | 8.3% | 1 | 0 | 29.0% | 11 | 0 | 0.2482 |
| Modified Rodnan skin score (0–51) | 5.7 | 8.9 | 0 | 8.5 | 9.3 | 0 | 0.1982 | 4.3 | 3.6 | 0 | 8.2 | 9.9 | 0 | 0.5419 | 5.0 | 4.1 | 0 | 8.2 | 10.2 | 0 | 0.8819 |
| Raynaud phenomenon | 100.0% | 19 | 0 | 93.6% | 29 | 0 | 0.5192 | 100.0% | 10 | 0 | 95.0% | 38 | 0 | 1.0000 | 100.0% | 12 | 0 | 94.7% | 36 | 0 | 1.0000 |
| Sclerodactyly | 79.0% | 15 | 0 | 80.7% | 25 | 0 | 1.0000 | 90.0% | 9 | 0 | 77.5% | 31 | 0 | 0.6631 | 83.3% | 10 | 0 | 79.0% | 30 | 0 | 1.0000 |
| Calcinosis | 31.6% | 6 | 0 | 19.4% | 6 | 0 | 0.4963 | 20.0% | 2 | 0 | 25.0% | 10 | 0 | 1.0000 | 25.0% | 3 | 0 | 23.7% | 9 | 0 | 1.0000 |
| Esophageal dysmotility | 57.9% | 11 | 0 | 63.3% | 19 | 1 | 0.7034 | 40.0% | 4 | 0 | 66.7% | 26 | 1 | 0.1565 | 41.7% | 5 | 0 | 67.6% | 25 | 1 | 0.1727 |
| Telangiectasias | 73.7% | 14 | 0 | 71.0% | 22 | 0 | 0.8355 | 80.0% | 8 | 0 | 70.0% | 28 | 0 | 0.7042 | 75.0% | 9 | 0 | 71.1% | 27 | 0 | 1.0000 |
| Abnormal nailfold capillaroscopy | 84.2% | 16 | 0 | 62.1% | 18 | 2 | 0.0989 | 100.0% | 10 | 0 | 63.2% | 24 | 2 | 0.0235 | 100.0% | 12 | 0 | 61.1% | 22 | 2 | 0.0101 |
| Digital pits | 42.1% | 8 | 0 | 40.0% | 12 | 1 | 0.8838 | 60.0% | 6 | 0 | 35.9% | 14 | 1 | 0.2794 | 50.0% | 6 | 0 | 37.8% | 14 | 1 | 0.5123 |
| Digital ulcers | 42.1% | 8 | 0 | 41.9% | 13 | 0 | 0.9906 | 50.0% | 5 | 0 | 40.0% | 16 | 0 | 0.7232 | 41.7% | 5 | 0 | 42.1% | 16 | 0 | 1.0000 |
| Interstitial lung disease | 31.6% | 6 | 0 | 19.4% | 6 | 0 | 0.4963 | 50.0% | 5 | 0 | 17.5% | 7 | 0 | 0.0460 | 41.7% | 5 | 0 | 18.4% | 7 | 0 | 0.1292 |
| Pulmonary hypertension | 0.0% | 0 | 1 | 10.0% | 3 | 1 | 0.2819 | 0.0% | 0 | 0 | 7.9% | 3 | 2 | 1.0000 | 0.0% | 0 | 1 | 8.1% | 3 | 1 | 1.0000 |
| Cardiac involvement | |||||||||||||||||||||
| EF < 50%, % | 0.0% | 0 | 1 | 3.9% | 1 | 5 | 1.0000 | 0.0% | 0 | 0 | 2.9% | 1 | 6 | 1.0000 | 0.0% | 0 | 1 | 3.0% | 1 | 5 | 1.0000 |
| Taking drugs for heart failure, % | 0.0% | 0 | 0 | 9.7% | 3 | 0 | 0.2788 | 0.0% | 0 | 0 | 7.5% | 3 | 0 | 1.0000 | 0.0% | 0 | 0 | 7.9% | 3 | 0 | 1.0000 |
| Taking antiarrhythmics, % | 0.0% | 0 | 0 | 0.0% | 0 | 0 | — | 0.0% | 0 | 0 | 0.0% | 0 | 0 | — | 0.0% | 0 | 0 | 0.0% | 0 | 0 | — |
| FVC, % predicted | 91.5 | 14.6 | 0 | 90.9 | 15.6 | 0 | 0.7490 | 94.3 | 14.8 | 0 | 90.3 | 15.2 | 0 | 0.3889 | 96.3 | 14.5 | 0 | 89.5 | 15.1 | 0 | 0.1426 |
| DLCO, % predicted | 70.7 | 20.9 | 0 | 69.7 | 17.5 | 0 | 0.9124 | 73.7 | 17.3 | 0 | 69.2 | 19.1 | 0 | 0.5046 | 74.3 | 15.7 | 0 | 68.8 | 19.5 | 0 | 0.4133 |
| History of scleroderma renal crisis | 5.3% | 1 | 0 | 3.3% | 1 | 1 | 1.0000 | 0.0% | 0 | 0 | 5.1% | 2 | 1 | 1.0000 | 0.0% | 0 | 0 | 5.4% | 2 | 1 | 1.0000 |
| Proteinuria | 2 | 3 | 1.0000 | 1 | 4 | 1.0000 | 1 | 4 | 1.0000 | ||||||||||||
| 0 | 0.0% | 0 | 96.4% | 27 | 0.0% | 0 | 97.2% | 35 | 100.0% | 11 | 0 | 97.1% | 33 | 0 | |||||||
| 1–2 | 0.0% | 0 | 3.6% | 1 | 0.0% | 0 | 2.8% | 1 | 0.0% | 0 | 0 | 2.9% | 1 | 0 | |||||||
| > 3 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0 | 0.0% | 0 | 0 | |||||||
| History of inflammatory myopathy | 0.0% | 0 | 1 | 22.6% | 7 | 0 | 0.0377 | 0.0% | 0 | 0 | 18.0% | 7 | 1 | 0.3186 | 0.0% | 0 | 0 | 18.9% | 7 | 1 | 0.1712 |
| History of arthritis | 16.7% | 3 | 1 | 17.2% | 5 | 2 | 1.0000 | 10.0% | 1 | 0 | 18.9% | 7 | 3 | 0.6673 | 16.7% | 2 | 0 | 17.1% | 6 | 3 | 1.0000 |
| Joint contractures | 10.5% | 2 | 0 | 9.7% | 3 | 0 | 1.0000 | 0.0% | 0 | 0 | 12.5% | 5 | 0 | 0.5687 | 8.3% | 1 | 0 | 10.5% | 4 | 0 | 1.0000 |
| CRP (mg/l) | 6.4 | 11.8 | 3 | 13.1 | 25.1 | 3 | 0.0522 | 5.0 | 8.6 | 1 | 12.1 | 23.4 | 5 | 0.0269 | 4.8 | 7.7 | 1 | 12.6 | 24.0 | 5 | 0.0651 |
| Overlap with other CTD | 0.0% | 0 | 0 | 16.1% | 5 | 0 | 0.1424 | 0.0% | 0 | 0 | 12.5% | 5 | 0 | 0.5687 | 0.0% | 0 | 0 | 13.2% | 5 | 0 | 0.3192 |
| Global assessment of severity (0–10) | 2.1 | 1.6 | 0 | 2.9 | 2.8 | 0 | 0.7196 | 1.7 | 0.7 | 0 | 2.8 | 2.7 | 0 | 0.5585 | 1.7 | 0.7 | 0 | 2.9 | 2.7 | 0 | 0.4416 |
| Global assessments of activity (0–10) | 2.5 | 2.9 | 0 | 2.3 | 2.5 | 0 | 0.8617 | 2.3 | 2.8 | 0 | 2.4 | 2.6 | 0 | 0.9702 | 2.9 | 3.4 | 0 | 2.2 | 2.4 | 0 | 0.5448 |
| Global assessments of damage (0–10) | 2.2 | 1.7 | 0 | 3.2 | 2.5 | 0 | 0.2306 | 2.1 | 1.5 | 0 | 3.0 | 2.4 | 0 | 0.3447 | 2.2 | 1.4 | 0 | 3.1 | 2.5 | 0 | 0.4632 |
P values in bold face are statistical y significant. ACR: American College of Rheumatology; CRP: C-reactive protein; CTD: connective tissue diseases; EF: ejection fractions.